Cargando…
P917: HOW COMORBID ARE OUR MYELOMA PATIENTS AND HOW MANY MAKE IT TO THE SECOND-LINE TREATMENT: REAL-WORLD DATA OF 251 MYELOMA PATIENTS TREATED IN THE HEMATOLOGICAL NETWORK OF THE OEGK
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431321/ http://dx.doi.org/10.1097/01.HS9.0000846536.28395.e7 |
| _version_ | 1784780022381281280 |
|---|---|
| author | Keil, F. Attalla, P. |
| author_facet | Keil, F. Attalla, P. |
| author_sort | Keil, F. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9431321 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-94313212022-08-31 P917: HOW COMORBID ARE OUR MYELOMA PATIENTS AND HOW MANY MAKE IT TO THE SECOND-LINE TREATMENT: REAL-WORLD DATA OF 251 MYELOMA PATIENTS TREATED IN THE HEMATOLOGICAL NETWORK OF THE OEGK Keil, F. Attalla, P. Hemasphere Posters Lippincott Williams & Wilkins 2022-06-23 /pmc/articles/PMC9431321/ http://dx.doi.org/10.1097/01.HS9.0000846536.28395.e7 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Keil, F. Attalla, P. P917: HOW COMORBID ARE OUR MYELOMA PATIENTS AND HOW MANY MAKE IT TO THE SECOND-LINE TREATMENT: REAL-WORLD DATA OF 251 MYELOMA PATIENTS TREATED IN THE HEMATOLOGICAL NETWORK OF THE OEGK |
| title | P917: HOW COMORBID ARE OUR MYELOMA PATIENTS AND HOW MANY MAKE IT TO THE SECOND-LINE TREATMENT: REAL-WORLD DATA OF 251 MYELOMA PATIENTS TREATED IN THE HEMATOLOGICAL NETWORK OF THE OEGK |
| title_full | P917: HOW COMORBID ARE OUR MYELOMA PATIENTS AND HOW MANY MAKE IT TO THE SECOND-LINE TREATMENT: REAL-WORLD DATA OF 251 MYELOMA PATIENTS TREATED IN THE HEMATOLOGICAL NETWORK OF THE OEGK |
| title_fullStr | P917: HOW COMORBID ARE OUR MYELOMA PATIENTS AND HOW MANY MAKE IT TO THE SECOND-LINE TREATMENT: REAL-WORLD DATA OF 251 MYELOMA PATIENTS TREATED IN THE HEMATOLOGICAL NETWORK OF THE OEGK |
| title_full_unstemmed | P917: HOW COMORBID ARE OUR MYELOMA PATIENTS AND HOW MANY MAKE IT TO THE SECOND-LINE TREATMENT: REAL-WORLD DATA OF 251 MYELOMA PATIENTS TREATED IN THE HEMATOLOGICAL NETWORK OF THE OEGK |
| title_short | P917: HOW COMORBID ARE OUR MYELOMA PATIENTS AND HOW MANY MAKE IT TO THE SECOND-LINE TREATMENT: REAL-WORLD DATA OF 251 MYELOMA PATIENTS TREATED IN THE HEMATOLOGICAL NETWORK OF THE OEGK |
| title_sort | p917: how comorbid are our myeloma patients and how many make it to the second-line treatment: real-world data of 251 myeloma patients treated in the hematological network of the oegk |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431321/ http://dx.doi.org/10.1097/01.HS9.0000846536.28395.e7 |
| work_keys_str_mv | AT keilf p917howcomorbidareourmyelomapatientsandhowmanymakeittothesecondlinetreatmentrealworlddataof251myelomapatientstreatedinthehematologicalnetworkoftheoegk AT attallap p917howcomorbidareourmyelomapatientsandhowmanymakeittothesecondlinetreatmentrealworlddataof251myelomapatientstreatedinthehematologicalnetworkoftheoegk |